Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for beast cancer

We evaluated the feasibility and incidence of hematological toxicity in a series of 39 breast cancer patients treated at our Institute with doxorubicin plus cyclophosphamide (AC) followed by docetaxel, using prophylactic G-CSF (Pegfilgrastim). We prescribed G-CSF as secondary prophylaxis during the AC regimen and as primary prophylaxis during treatment with docetaxel. For the AC treatment, we recorded 6 cases of grade III (15.3%) and one case of grade IV (2.5%) neutropenia; we found one case of Grade IV anemia. For the docetaxel regimen, we registered one case of Grade IV (2.5%) neutropenia and three cases of Grade III leukopoenia without neutropenia. No patients experienced cardiac symptoms or baseline LVEF rate decrease. All patients concluded the programmed chemotherapy. Our experience shows the safety of docetaxel in combination with anthracyclines and the efficacy of prophylaxis with G-CSF in breast cancer adjuvant chemotherapy.